CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0001678: Atrioventricular blockHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug469 COVID-19 antibodies testing Wiki 1.00

Correlated MeSH Terms (5)


Name (Synonyms) Correlation
D016171 Torsades de Pointes NIH 1.00
D001919 Bradycardia NIH 1.00
D054537 Atrioventricular Block NIH 1.00
D001281 Atrial Fibrillation NIH 1.00
D001145 Arrhythmias, Cardiac NIH 0.58

Correlated HPO Terms (4)


Name (Synonyms) Correlation
HP:0004757 Paroxysmal atrial fibrillation HPO 1.00
HP:0001664 Torsade de pointes HPO 1.00
HP:0001662 Bradycardia HPO 1.00
HP:0011675 Arrhythmia HPO 0.58

There is one clinical trial.

Clinical Trials


1 COVIDAR - International Registry on Arrhythmias in COVID-19

BACKGROUND AND RATIONALE: There is very limited literature available on the arrhythmia occurrence in the context of an infection by the SARS-CoV2 virus. On the other hand, treatment strategies against the SARS-CoV2 virus may carry a risk of QTc prolongation and pro-arrhythmia/sudden death which may be amplified by concomitant use of other QTc-prolonging drugs and/or ion disbalances. COVIDAR is an international initiative to monitor the occurrence of arrhythmic events in the context of the SARS-CoV2 infection, to identify potential modifiable predisposing factors to reduce their incidence and to inform the best arrhythmia management options in this patient population. MAIN OBJECTIVE: To describe the incidence and type of arrhythmic events in the context of the SARS-CoV2 infection. STUDY DESIGN: patient registry (observational). Patients will not undergo any additional investigations. Only data that is generated during routine clinical care will be collected. STUDY POPULATION: Patients admitted to the hospital highly suspected of or with confirmed COVID-19.

NCT04437901 COVID Arrhythmia Torsades de Pointe Caused by Drug Qt Interval, Variation in Atrioventricular Block Atrial Fibrillation Bradyarrhythmia Ventricular Arrythmia
MeSH:Atrial Fibrillation Arrhythmias, Cardiac Atrioventricular Block Bradycardia Torsades de Pointes
HPO:Arrhythmia Atrial fibrillation Atrioventricular block Bradycardia Paroxysmal atrial fibrillation Torsade de pointes

Primary Outcomes

Description: Any arrhythmic event occurring in COVID-19 patients during hospital admission: Monomorphic ventricular tachycardia Polymorphic ventricular tachycardia/Torsades de pointes (non-sustained) Ventricular fibrillation AV-block Severe bradycardia, symptomatic and/or requiring treatment New-onset atrial fibrillation Other

Measure: Arrhythmia

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

Secondary Outcomes

Description: Categorical variable collecting the patient's underlying rhythm at baseline, on treatment and in case of arrhythmic adverse events): sinus rhythm, atrial fibrillation/flutter, other

Measure: Electrocardiographic changes - Underlying rhythm

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

Description: Collected as a categorical (normal, 1st-, 2nd- or 3rd degree AV block) and a continuous (PR duration in ms) at baseline, on treatment and in case of arrhythmic adverse events)

Measure: Electrocardiographic changes - Atrioventricular conduction

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

Description: Collected as a continuous variable (ms) at baseline, on treatment and in case of arrhythmic adverse events)

Measure: Electrocardiographic changes - QRS duration

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

Description: Collected as a categorical variable (not present, type 1 or type 2) at baseline, on treatment and in case of arrhythmic adverse events)

Measure: Electrocardiographic changes - presence of Brugada QRS pattern

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

Description: Collected as a continuous variable (ms) at baseline, on treatment and in case of arrhythmic adverse events)

Measure: Electrocardiographic changes - QTc duration

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

Description: Kalium, magnesium and calcium collected as continuous variables at baseline, on treatment and in case of arrhythmic adverse events). Will be reported as a categorical variable (presence/absence) of electrolyte misbalance

Measure: Laboratory abnormalities - electrolyte misbalance

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

Description: Cardiac CK, troponin T and/or troponin I (where available) collected as a continuous variable at baseline, on treatment and in case of arrhythmic adverse events)

Measure: Laboratory abnormalities - cardiac biomarkers

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

Description: Creatinine clearance at baseline, on treatment and in case of arrhythmic adverse events)

Measure: Laboratory abnormalities - renal function

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

Description: Liver enzymes collected at at baseline, on treatment and in case of arrhythmic adverse events)

Measure: Laboratory abnormalities - liver function

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months


HPO Nodes